Robin David Isaacs is joining Entasis Therapeutics as its chief medical officer. The Waltham, MA-based company is a spinout of AstraZeneca and is focused on creating novel antibiotics with a pathogen-targeted approach. The company’s lead candidate is ETX0914, a treatment of uncomplicated gonorrhea in Phase 2. Isaacs comes from Merck, where he worked for 18 years and was most recently vice president and therapeutic area head for vaccine clinical research.
Author: David Holley
David is the national correspondent at Xconomy. He has spent most of his career covering business of every kind, from breweries in Oregon to investment banks in New York. A native of the Pacific Northwest, David started his career reporting at weekly and daily newspapers, covering murder trials, city council meetings, the expanding startup tech industry in the region, and everything between. He left the West Coast to pursue business journalism in New York, first writing about biotech and then private equity at The Deal. After a stint at Bloomberg News writing about high-yield bonds and leveraged loans, David relocated from New York to Austin, TX.
He graduated from Portland State University.
View all posts by David Holley
